MX380642B - Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). - Google Patents
Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).Info
- Publication number
- MX380642B MX380642B MX2016016742A MX2016016742A MX380642B MX 380642 B MX380642 B MX 380642B MX 2016016742 A MX2016016742 A MX 2016016742A MX 2016016742 A MX2016016742 A MX 2016016742A MX 380642 B MX380642 B MX 380642B
- Authority
- MX
- Mexico
- Prior art keywords
- ceramide
- group
- complications
- ceramides
- cvd
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462012543P | 2014-06-16 | 2014-06-16 | |
| US14/677,595 US9347960B2 (en) | 2014-06-16 | 2015-04-02 | Ceramides and their use in diagnosing CVD |
| PCT/EP2015/063492 WO2015193325A2 (en) | 2014-06-16 | 2015-06-16 | Ceramides and their use in diagnosing cvd |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016742A MX2016016742A (es) | 2017-04-27 |
| MX380642B true MX380642B (es) | 2025-03-12 |
Family
ID=54835950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016742A MX380642B (es) | 2014-06-16 | 2015-06-16 | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9347960B2 (enExample) |
| EP (2) | EP3155440B1 (enExample) |
| JP (1) | JP6774879B2 (enExample) |
| KR (3) | KR102636885B1 (enExample) |
| CN (1) | CN106461685B (enExample) |
| CA (1) | CA2951578A1 (enExample) |
| MX (1) | MX380642B (enExample) |
| SA (1) | SA516380503B1 (enExample) |
| SG (1) | SG11201609621RA (enExample) |
| WO (1) | WO2015193325A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| US10996231B2 (en) * | 2014-12-16 | 2021-05-04 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| US12313634B2 (en) * | 2017-11-20 | 2025-05-27 | Zora Biosciences Oy | Methods for prediction and early detection of diabetes |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2020112149A1 (en) * | 2018-12-01 | 2020-06-04 | Binhai Industrial Technology Research Institute Of Zhejiang University | Methods and compositions for the assessment of acute myocardial infarction (ami) |
| SG11202105172PA (en) * | 2018-12-06 | 2021-06-29 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN112730638B (zh) * | 2020-11-25 | 2022-07-29 | 首都医科大学附属北京朝阳医院 | 糖尿病合并心梗代谢标志物、检测试剂及试剂盒 |
| CN112986454A (zh) * | 2021-05-18 | 2021-06-18 | 天津云检医疗器械有限公司 | 急性心肌梗死的血清标志物、试剂盒和用途 |
| CN113495160B (zh) * | 2021-09-07 | 2021-11-19 | 宝枫生物科技（北京）有限公司 | 用于诊断高原环境下的缺血缺氧性脑病补充神经酸起效的分子标志物及其应用 |
| WO2023108294A1 (en) * | 2021-12-17 | 2023-06-22 | National Research Council Of Canada | Diagnostic lipid biomarkers for covid-19 and methods for use thereof |
| CN116500179B (zh) * | 2023-04-21 | 2023-12-26 | 南京品生医疗科技有限公司 | 一种血浆中神经酰胺相关因子的原始得分计算及转换方法和系统 |
| CN119198939B (zh) * | 2024-08-30 | 2025-06-03 | 北京大学第三医院（北京大学第三临床医学院） | 神经酰胺的检测试剂盒、应用检测试剂盒检测神经酰胺的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2787297C (en) | 2010-01-29 | 2018-09-04 | Metanomics Gmbh | Means and methods for diagnosing heart failure in a subject |
| ES2455124T5 (es) | 2010-05-05 | 2018-05-08 | Zora Biosciences Oy | Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca |
| US9201080B2 (en) | 2010-06-20 | 2015-12-01 | Zora Biosciences Oy | Lipidomic biomarkers for identification of high-risk coronary artery disease patients |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| CA2841915A1 (en) | 2011-07-28 | 2013-01-31 | Metanomics Gmbh | Means and methods for diagnosing and monitoring heart failure in a subject |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2909626B1 (en) | 2012-10-18 | 2018-07-04 | metanomics GmbH | Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample |
| EP2965092A1 (en) | 2013-03-08 | 2016-01-13 | Zora Biosciences OY | Non-high density lipoprotein derived cvd markers |
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
-
2015
- 2015-04-02 US US14/677,595 patent/US9347960B2/en active Active
- 2015-06-16 KR KR1020177000864A patent/KR102636885B1/ko active Active
- 2015-06-16 SG SG11201609621RA patent/SG11201609621RA/en unknown
- 2015-06-16 EP EP15733650.4A patent/EP3155440B1/en active Active
- 2015-06-16 EP EP22168767.6A patent/EP4089416A1/en active Pending
- 2015-06-16 WO PCT/EP2015/063492 patent/WO2015193325A2/en not_active Ceased
- 2015-06-16 KR KR1020247004744A patent/KR102864779B1/ko active Active
- 2015-06-16 JP JP2016573763A patent/JP6774879B2/ja active Active
- 2015-06-16 MX MX2016016742A patent/MX380642B/es unknown
- 2015-06-16 CN CN201580031908.1A patent/CN106461685B/zh active Active
- 2015-06-16 CA CA2951578A patent/CA2951578A1/en not_active Abandoned
- 2015-06-16 KR KR1020257030977A patent/KR20250139419A/ko active Pending
-
2016
- 2016-05-19 US US15/159,650 patent/US10197582B2/en active Active
- 2016-12-15 SA SA516380503A patent/SA516380503B1/ar unknown
-
2018
- 2018-12-12 US US16/218,363 patent/US11474116B2/en active Active
-
2022
- 2022-02-10 US US17/668,927 patent/US11940453B2/en active Active
-
2024
- 2024-02-14 US US18/441,255 patent/US20240183866A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3155440B1 (en) | 2022-04-20 |
| KR102636885B1 (ko) | 2024-02-19 |
| JP6774879B2 (ja) | 2020-10-28 |
| KR20240023696A (ko) | 2024-02-22 |
| CN106461685B (zh) | 2021-05-25 |
| US20240183866A1 (en) | 2024-06-06 |
| EP4089416A1 (en) | 2022-11-16 |
| KR20250139419A (ko) | 2025-09-23 |
| US20220163547A1 (en) | 2022-05-26 |
| EP3155440A2 (en) | 2017-04-19 |
| KR20170018905A (ko) | 2017-02-20 |
| JP2017519989A (ja) | 2017-07-20 |
| US20150362513A1 (en) | 2015-12-17 |
| US11940453B2 (en) | 2024-03-26 |
| MX2016016742A (es) | 2017-04-27 |
| BR112016028534A2 (pt) | 2017-08-22 |
| US20190113531A1 (en) | 2019-04-18 |
| WO2015193325A3 (en) | 2016-02-25 |
| US9347960B2 (en) | 2016-05-24 |
| SG11201609621RA (en) | 2017-01-27 |
| SA516380503B1 (ar) | 2023-03-23 |
| US11474116B2 (en) | 2022-10-18 |
| KR102864779B1 (ko) | 2025-09-25 |
| US10197582B2 (en) | 2019-02-05 |
| CA2951578A1 (en) | 2015-12-23 |
| US20160266152A1 (en) | 2016-09-15 |
| WO2015193325A2 (en) | 2015-12-23 |
| CN106461685A (zh) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380642B (es) | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). | |
| CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
| CL2020003416A1 (es) | Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268) | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BR112017018821A2 (pt) | métodos para quantificação de níveis de insulina através de espectrometria de massa | |
| BR112017017025A2 (pt) | métodos e composições para analizar componentes celulares | |
| MX2015012437A (es) | Esteroides neuroactivos, composiciones, y usos de los mismos. | |
| MX2016011377A (es) | Metodo para diagnosticar cancer colorrectal a partir de una muestra de heces humanas por pcr cuantitativa, cebadores y equipo. | |
| BR112019005167A2 (pt) | método e kit para analisar uma amostra | |
| EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
| EA201990730A1 (ru) | Рнк-биомаркеры для наследственного ангионевротического отека | |
| BR112022011676A2 (pt) | Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método | |
| MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
| ECSP13013092A (es) | Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo | |
| BR112016024730A2 (pt) | dispositivo, método e conjunto de análise imunocromatográfica | |
| EA201991506A1 (ru) | Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов | |
| ES2684758T3 (es) | Procedimiento para diagnosticar fibrosis hepática | |
| BR112017021507A2 (pt) | métodos para a seleção de inibidores seletivos e não seletivos de fosfatase | |
| WO2017097852A3 (en) | Use of ceramides and lpls in diagnosing cvd | |
| WO2015189591A3 (en) | Method and arrays for use in diagnosing early breast cancer | |
| BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
| MX378728B (es) | Ensayo de inflamacion oral. | |
| MX2024009782A (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto. | |
| WO2015193552A3 (en) | Means and methods for determining risk of type-1 diabetes by serum protein biomarkers | |
| PL407244A1 (pl) | Bioczujnik elektrochemiczny do wykrywania białka S100B |